GlassScriptPhysician profile
Billy C Weitherspoon
NPI 1013398155
$1,234.03
in general payments reported to CMS, 2019-2025
11 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $280.39 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $165.59 | 2025 | Austedo Xr, Uzedy |
| Lundbeck LLC | $142.80 | 2025 | Rexulti |
| Braeburn INC. | $125.00 | 2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.83 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $119.54 | 2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $116.10 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $107.10 | 2025 | Auvelity |
| Alkermes, INC. | $23.70 | 2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $16.18 | 2025 | Cobenfy |
| Luye Pharma (USA) LTD. | $15.80 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Weitherspoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.